行情

ACAD

ACAD

阿卡迪亚
NASDAQ

实时行情|Nasdaq Last Sale

42.60
-1.41
-3.20%
已收盘, 19:56 09/17 EDT
开盘
44.00
昨收
44.01
最高
44.64
最低
41.13
成交量
338.80万
成交额
--
52周最高
44.85
52周最低
13.87
市值
61.55亿
市盈率(TTM)
-21.6507
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ACAD 新闻

  • 5 Stocks To Watch For September 18, 2019
  • Benzinga.1小时前
  • ACADIA Pharmaceuticals Prices 6,25M Share Public Offering of Common Stock @$40/Share
  • Benzinga.1小时前
  • Acadia Pharma launches $250M stock offering; sharess down 4% after hours
  • seekingalpha.9小时前
  • ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
  • Business Wire.13小时前

更多

所属板块

生物技术和医学研究
+0.26%
制药与医学研究
+0.57%

热门股票

名称
价格
涨跌幅

ACAD 简况

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
展开

Webull提供ACADIA Pharmaceuticals Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。